Terug
Ook genoteerd als
HLN
NYSE
Dagbereik
€ 4,94
€ 5,00
52-Weeksbereik
€ 4,25
€ 5,80
Volume
2.504
50D / 200D Gem.
€ 5,22
/
€ 4,92
Vorige Slotkoers
€ 5,30
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 26,7 | 0,4 |
| P/B | 2,7 | 2,9 |
| ROE % | 10,2 | 3,7 |
| Net Margin % | 15,1 | 3,9 |
| Rev Growth 5Y % | 3,7 | 10,0 |
| D/E | 0,5 | 0,2 |
Belangrijkste Punten
Revenue grew 3,68% annually over 5 years — modest growth
Earnings grew 15,58% over the past year
ROE of 10,23% — decent returns on equity
Net margin of 15,11% shows strong profitability
Generating 2,01B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 5,50%
Groei
Revenue Growth (5Y)
3,68%
Revenue (1Y)-1,82%
Earnings (1Y)15,58%
FCF Growth (3Y)6,87%
Kwaliteit
Return on Equity
10,23%
ROIC7,41%
Net Margin15,11%
Op. Margin22,44%
Veiligheid
Debt / Equity
0,52
Current Ratio0,92
Interest Coverage7,28
Waardering
P/E Ratio
26,72
P/B Ratio2,71
EV/EBITDA20,94
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -1,82% | Revenue Growth (3Y) | -1,22% |
| Earnings Growth (1Y) | 15,58% | Earnings Growth (3Y) | 26,05% |
| Revenue Growth (5Y) | 3,68% | Earnings Growth (5Y) | 4,64% |
| Profitability | |||
| Revenue (TTM) | 11,03B | Net Income (TTM) | 1,67B |
| ROE | 10,23% | ROA | 5,11% |
| Gross Margin | 64,77% | Operating Margin | 22,44% |
| Net Margin | 15,11% | Free Cash Flow (TTM) | 2,01B |
| ROIC | 7,41% | FCF Growth (3Y) | 6,87% |
| Safety | |||
| Debt / Equity | 0,52 | Current Ratio | 0,92 |
| Interest Coverage | 7,28 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 26,72 | P/B Ratio | 2,71 |
| P/S Ratio | 4,04 | PEG Ratio | 1,06 |
| EV/EBITDA | 20,94 | Dividend Yield | 0,02% |
| Market Cap | 44,53B | Enterprise Value | 51,81B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11,03B | 11,23B | 11,30B | 10,86B | 9,55B |
| Net Income | 1,67B | 1,44B | 1,05B | 1,06B | 1,39B |
| EPS (Diluted) | 0,19 | 0,16 | 0,11 | 0,11 | 0,15 |
| Gross Profit | 7,14B | 6,82B | 6,96B | 6,58B | 5,95B |
| Operating Income | 2,47B | 2,21B | 2,00B | 1,83B | 1,64B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 32,62B | 34,32B | 34,06B | 34,82B | 34,45B |
| Total Liabilities | 16,14B | 18,09B | 17,33B | 18,36B | 7,97B |
| Shareholders' Equity | 16,42B | 16,17B | 16,61B | 16,33B | 26,36B |
| Total Debt | 8,61B | 10,10B | 9,46B | 10,44B | 991,00M |
| Cash & Equivalents | 1,32B | 2,20B | 1,04B | 684,00M | 414,00M |
| Current Assets | 4,55B | 5,72B | 4,82B | 4,06B | 5,25B |
| Current Liabilities | 4,93B | 5,81B | 4,64B | 4,37B | 4,24B |